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ABSTRACT
Objective: This study aims to assess the condition of cardiac histopathology through hematoxylin-eosin staining in 5/6 subtotal nephrectomy 
conditions.
Methods: Fifteen male Swiss mice aged 3–5 months will be grouped into 3 treatment groups, namely the nephrectomy group (JSN, n=5), sham 
operation (JSO, n=5), and simvastatin 20 mg/kg body weight (JSIM, n=5). The histopathology of the heart will be assessed blindly. Severity is assessed 
based on scoring using a scale (−) no damage, (+) mild, (++) medium, and (+++) heavy. Assessment of severity refers to the irregularity of the heart 
muscle, increased amount of connective tissue, myofibril hypertrophy, myofibril swelling, sarcoplasmic fragmentation, sarcoplasmic vacuolization, 
bleeding in a myofibril, myofibril degeneration, cardiomyocyte damage, and the presence of acidophilic cytoplasm.
Results: The results showed no morphological changes in heart muscle tissue in the JSO group except for fragmentation and vacuolization in minimal 
amounts of sarcoplasm (+), whereas in the JSN and JSIM groups, there was moderate damage to sarcoplasm (++) and minimal changes in myofibrils 
(hypertrophy and bleeding) (+). The JSN group also found severe damage (+++) to the irregularity of the heart muscle, whereas in JSIM, only moderate 
damage was found (++) to the irregularity of the heart muscle.
Conclusion: Simvastatin seems to be able to correct the irregularity of the heart muscle in the condition of 5/6 subtotal nephrectomy.
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INTRODUCTION
Cardiovascular disease is a condition that often occurs in patients 
with chronic renal failure (CRF). This condition increases the 
risk of death in patients. The prevalence of this disease also 
increases with increasing severity of kidney function [1-3]. The 
cardiovascular events that often occur are heart failure. This 
disease is estimated to have affected 23 million world populations, 
where the prevalence was higher in CRF patients than without CRF 
(63% vs. 5.8%) [3-5]. In the United States, this disease is the main 
cause of hospitalization [6].
Statins are very potent 3-hydroxy-3-methyl-3-methylglutaryl-
coenzyme A reductase inhibitors. Besides its ability to inhibit 
cholesterol biosynthesis and reduce serum levels of low-density 
lipoprotein (LDL) cholesterol, statins have also been reported to have 
pleiotropic effects such as anti-inflammatory, antioxidants and improve 
endothelial function and angiogenesis. Statins are widely used in 
chronic ischemic heart disease and show improvement in endothelial 
function through increased production of endogenous nitric oxide, 
C-reactive protein, oxidized LDL, and cytokines such as tumor necrosis 
factor α and interleukin-6 [7].
Heart failure is characterized by systemic and vascular inflammation 
characterized by an increase in inflammatory biomarker and adhesion 
molecules [6]. The previous study shows that simvastatin therapy for 
14 days was able to improve the fibrosis condition. However, the exact 
mechanism is not yet known [8]. For this reason, further research is 
needed to assess the condition of heart histopathology in more detail. 
This study aims to determine the histopathology of the heart in the CRF 
condition using animal models.
METHODS
Drug
Simvastatin (Sigma-Aldrich, Singapore) was dissolved in a 1% solution 
of carboxymethyl cellulose (CMC) (Sigma-Aldrich, St Louis, USA). 
Simvastatin is given orally once a day for 14 days.
Animals
In this study, eighteen male Swiss mice with weighing 30–40 g 
were purchased from the experimental animal research center, 
Universitas Udayana, Denpasar. All mice were housed according 
to the treatment group at room temperature about 22±2°C and 
humidity about 50±5% with a 12–12 h light-dark cycle. They had 
free access to tap water and about 3–5 g standard food per day. This 
study was approved by Komite Etik Penelitian Fakultas Kedokteran 
Universitas Udayana/Rumah Sakit Umum Pusat Sanglah Denpasar 
No: 2125/UN14.2.2.VII.14/LP/2018.
Experimental protocol
All mice were randomized and acclimatized for 7 days. The mice were 
grounded according to the treatment group. Mice were divided in three 
groups (n=6) including sham group (JSO, group with only incision on 
the both sides of the flank region but there is no intervention on the 
kidney and 1% CMC solution), 5/6 subtotal nephrectomy group (JSN, 
group with nephrectomy on right kidney and ablation on superior 
and inferior part of the left kidney and simvastatin 20 mg/kg body 
weight [BW]), and simvastatin group (JSIM, group with 5/6 subtotal 
nephrectomy group and simvastatin 20 mg/kg BW) [9,10]. Animals 
were anesthetized using a combination of ketamine (90 mg/kg BW) 
and xylazine (10 mg/kb BW) through intraperitoneal injection. At the 
end of the study, the hearts were obtained from all the animals.
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Histopathological assessment
For histopathological analyses, isolated hearts fixed in 10% buffer 
formalin. The samples dehydrated with ethanol and embedded in 
paraffin. Sections with 4 µm thickness were cut and stained with 
hematoxylin-eosin (HE). Cardiac histopathology analysis includes 
cardiac muscle regularity, increased connective tissue, myofibril 
hypertrophy, swelling, sarcoplasmic fragmentation and vacuolization, 
bleeding and degeneration of myofibrils, cardiomyocyte damage, and 
the presence or absence of acidophilic cytoplasm. Assessment is based 
on observations of 10 view fields with ×400 magnification. Histological 
changes scored on a 4-point scale: (−) none, (+) mild, (++) moderate, 
and (+++) severe damage [11]. The morphological measurement was 

















JSO − − + − − −
JSN +++ + ++ + − −
JSIM ++ + ++ + − −
aScale: (–) none, (+) mild, (++) moderate, (+++) severe damage. HE: Hematoxylin-eosin
Fig. 2: Semiquantitative histological changes in the heart in each group. *Versus JSO, #versus JSIM
performed blindly. Furthermore, we analyze semi-quantitatively by 
giving a score of 0–3 based on the average point of scale obtained 
(0=0–0.5; 1≥0.5–1.5; 2≥1.5–2.5; 3≥2.5).
Statistical analyses
We used the SPSS 18.0 software for data processing. The results 
were expressed as the mean ± standard deviation. The results 
were analyzed by one-way ANOVA followed by Tukey test for data 
that normally distributed and Mann–Whitney test for data that not 
normally distributed. p<0.05 was considered statistically significant.
RESULTS AND DISCUSSION
The results of this study showed that there were no morphological 
changes in the heart muscle tissue in the JSO group except for slight 
fragmentation and vacuolization of sarcoplasm. Whereas in the JSN 
and JSIM groups, there were moderate damage to sarcoplasm (++) 
and minimal changes in myofibrils (hypertrophy and bleeding) (+). 
The JSN group also found severe damage (+++) on the heart muscle, 
whereas JSIM found only moderate damage (++) (Table 1 and 
Fig. 1).
Based on the results of the average total point of the scale, it was 
found that there were significant differences in cardiac muscle 
irregularities between JSO versus JSN groups (0.20±0.27 vs. 
2.27±0.46), p=0.00 and JSO versus JSIM (0.20±0.27 vs. 1.75±0.51), 
p=0.00. However, there was no significant difference between the 
Fig. 1: Cardiac histopathology on each group with hematoxylin-
eosin staining, (a) JSO group, (b) JSN group, (c) JSIM group. 
Magnification ×400
a b c
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JSN versus JSIM group, p=0.11. Similar results were also found 
in hypertrophy and swelling myofibril conditions. There were 
significant differences between JSO versus JSN groups (0.10±0.24 vs. 
1.49±0.42), p=0.00 and JSO versus JSIM (0.10±0.24 vs. 1.37±0.45), 
p=0.00. However, there was no significant difference between the 
JSN versus JSIM groups, p=0.82. The assessment of sarcoplasm 
fragmentation and vacuolization also found similar data. There was 
a significant difference between JSO versus JSN group (0.53±0.29 vs. 
1.95±0.81), p=0.00 and JSO versus JSIM (0.53±0.29 vs. 1.57±0.52), 
p=0.02. However, there was no significant difference between JSN 
versus JSIM groups, p=0.53. There was no significant difference 
in the signs of hemorrhage and degeneration of myofibril in the 
treatment group (p=0.15). The analysis using Mann–Whitney test on 
the signs of shrinkage in myofibril and increasing connective tissue 
has significant differences in the JSO versus JSN and JSN versus JSIM 
groups, p<0.05 (Fig. 2).
Myocardial reactions to injury are more limited than many other 
tissues. Injury on myofibers is irreversible. The necrotic debris due 
to injury will be phagocytized and replaced by fibrous tissue. The 
uremic toxin has been demonstrated in vitro as a contributory factor 
in cardiac fibrosis and makes typical structural changes, “uremic 
cardiomyopathy” [12]. Based on the results of the cardiac biopsy 
in CRF patients, there is a change in the myocardial structure such 
as cardiomyocyte hypertrophy and myocardial fibrosis, as well as 
thickening of the arterial walls and arterioles. The fibrosis conditions 
mainly occur due to an imbalance of synthesis and degradation 
of collagen, in addition to the contribution of other factors such 
as excess fluid, inflammatory processes, oxidative stress, or due 
to worsening of the patient’s condition in CRF [12,13]. Treatment 
with a statin on CRF model seems able to decrease of vascular 
wall thickness significantly compared with the nephrectomy 
group [8]. This is possible because statins are known to have the 
ability to reduce oxidative stress and transforming growth factor 
beta (pro-inflammatory cytokines) and inhibit angiotensin II/Smad 
pathways [14,15].
In this study, fibrosis has not occurred in all treatment groups. The 
changes that occur are in the form of hypertrophy in the heart muscle. 
In general, pathological cardiac hypertrophy characterized by the 
thickening of the heart muscle, a decrease in the size of the chambers 
of the heart, and a reduced capacity of the heart to pump blood to the 
tissues and organs around the body [16].
CONCLUSION
The most prominent change in histopathology myocardium on the 
JSN group is the irregularity of the heart muscle. The administration 
of simvastatin seems to be able to correct the irregularity of the heart 
muscle but not statistically significant. The possibility of increasing the 
dose may have a better effect. However, the exact mechanism of the 
occurrence of this condition is not fully understood, so further research 
is still needed.
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